|Pre-clinical||Phase i/ii||Phase iii||NDA/MAA Filing|
GI & Inflammation
|RHB-105||H. pylori infections|
|Gastroenteritis & gastritis|
Oncology - GI/Inflammation
|YELIVA™ (ABC294640)||Multiple indications|
RedHill Biopharma (NASDAQ / TASE: RDHL) is an emerging Israeli biopharmaceutical company focused primarily on the development and acquisition of late clinical-stage, proprietary, orally-administered, small molecule drugs for the treatment of inflammatory and gastrointestinal diseases, including gastrointestinal cancers.